Akebia Therapeutics, Inc. AKBA

0.90 (0.02) (2.17%) as of 25 Sep
Market cap
$254.7M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio 0.00 3.59 1.54 2.23 1.32 1.77 0.39 1.22 2.50 1.75
P/FCF ratio 7.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.10
P/Operating CF 4.14 (39.76) (4.35) (8.12) (12.59) (5.97) (2.07) (103.15) (89.74) 13.30
P/B ratio 5.81 5.31 0.50 1.90 1.57 5.07 21.67 0.00 0.00 12.70
EV/Sales 0.00 1.84 1.11 2.03 0.88 1.94 0.30 1.18 2.53 1.25
EV/EBITDA 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.91
EV/FCF 2.46 (5.77) (2.33) (2.58) (2.30) (1.62) (1.21) (9.78) (9.96) 4.35
Current Ratio 2.59 2.54 1.76 1.49 1.98 1.04 1.43 1.18 1.41 1.55
Net Debt/EBITDA 1.92 4.21 0.51 0.27 0.56 (0.15) 0.57 0.96 1.02 (5.51)
Debt/Equity 0.00 0.00 0.02 0.20 0.41 2.49 12.63 (1.13) (0.79) 1.48
ROE (136.35%) (77.27%) (37.86%) (54.27%) (119.82%) (175.37%) (237.83%) 409.60% 174.03% 64.49%
ROA (61.26%) (22.17%) (21.10%) (31.64%) (54.38%) (48.07%) (21.28%) (17.37%) (30.02%) (1.79%)
ROIC 0.00% 0.00% (20.38%) (54.53%) (196.30%) (152.01%) 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets (73.51%) (33.36%) (68.18%) (250.15%) (199.49%) (1,673.53%) (154.82%) (237.01%) (197.65%) (5.86%)
Average Days of Receivables 8,042.60 68.91 410.54 42.61 82.81 88.95 50.27 73.69 78.31 72.68
Earnings Yield (34.29%) (12.76%) (44.67%) (37.34%) (98.93%) (75.22%) (82.26%) (22.05%) (17.37%) (1.06%)
Free Cash Flow Yield 13.95% (8.87%) (30.88%) (35.29%) (29.28%) (67.46%) (64.65%) (9.87%) (10.15%) 16.39%
Free Cash Flow per Share 1.46 (1.33) (1.71) (2.23) (0.80) (1.52) (0.40) (0.12) (0.19) 0.26
Book value per Share 1.81 2.82 10.96 3.33 1.79 0.45 0.03 (0.16) (0.23) 0.13
Free Cash Flow 55.24 (57.78) (99.10) (264.10) (110.70) (253.02) (73.27) (23.38) (40.69) 67.87
EV/EBIT 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.55
Other line items

Show all line items

Columns are period end dates